
We continue the series of educational articles on SR&ED related projects in the Cannabis Industry. This article will focus on the first stages of the SR&ED project.
To make sure that the correct amount of expenses is claimed, it is very important to determine when the SR&ED project begins. A common belief is that it starts when the technological obstacle is identified. This is, however, a mistake. First, it is required to show that the problem has no available solutions in the open sources. In other words – to perform a due-diligence research assessment. Although the Cannabis Industry is very new, answers to some of these questions can be found online, in scientific journals, in professional literature (e.g., The Cannabis Growth Bible) or by asking colleagues who might have had similar problems or questions before. The time spent on the due-diligence research assessment is not SR&ED eligible.
Let’s assume that no answers are found in the open sources. This result still does not mean that there is a real technological uncertainty and that the SR&ED projects have begun – there can be some available answers in parallel industries. For example, it is known that in some parameters the cannabis growth process can be comparable to this of tomatoes. In such case, if you try a method described for tomatoes and it does not lead to the expected results – only then one can say that a technological wall was hit and the SR&ED work begins.
Let’s assume we are at the beginning of the SR&ED project. To be eligible, the project has to follow an intelligent path, avoiding “trial and error” type of work. Thus, it is highly recommended at this stage, before starting with the experimental process, to write a short research protocol, which will serve a proof that the project is not “trial and error” type. This protocol may include the following chapters:
Such protocols will eventually become an important integrated part of the SR&ED technical description. As well – protocol formulation and the corresponding discussions time is SR&ED eligible, so do not forget to mention it in the timesheets.
For further information on the Medical Cannabis Industry, please contact us today.
Gregory Molev
Senior Science Advisor
Mobile: +1 647.972.6285
Email: gmolev@braithwaite.ca
900-2235 Sheppard Ave E
Toronto, ON M2J 5B5
Office: 1-416-499-2861
Email: info@braithwaite.ca
eFax: 1-437-889-0955
102-165 Saint-Zotique West
Montréal, QC H2S 1P5
Office: 1-514-495-6590
Email: contact@abgi-canada.com
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.